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© 2011 Japanese Society of Tropical Medicine Abstract: Reactive oxygen species (ROS) produced by neutrophils are crucial for defense against infectious diseases,
and the adequate measurement of ROS levels is an important way to evaluate the possibility of infections. The
fluorescent probe dihydrorhodamine 123 has been applied exclusively to the measurement of ROS thus far. We
developed a novel method for detecting ROS, which utilizes the chemiluminescent probes Luminol and Diogenes.
The new method quantitatively detects ROS produced by as few as 10 to 10
4 neutrophils. Furthermore, this method
can detect ROS levels in one microliter of whole blood or ROS produced by Epstein-Barr immortalized B
lymphocytes. This method will be valuable for prompt diagnosis of neonatal chronic granulomatous diseases in
which neutrophils aberrantly produce superoxide.
Key words: Phagocyte NADPH oxidase, Lucigenin, Luminol, Diogenes, superoxide
INTRODUCTION
Professional phagocytes, including neutrophils, eosino-
phils and monocytes, play a crucial role in host defense
against microbial infections [1]. During phagocytosis of
invading microorganisms or upon cell stimulation with arti-
ficial activators of protein kinase c (PKC) such as phorbol
myristate acetate (PMA), phagocytes produce superoxide, a
precursor of microbicidal reactive oxygen species (ROS),
by catalysis of activated phagocyte NADPH oxidase (Fig. 1
and 2) [2]. ROS derived from superoxide are essential for
microbial killing. The importance of phagocyte NADPH
oxidase is underlined by the genetic disorder known as
chronic granulomatous disease (CGD). The neutrophils of
CGD patients cannot produce superoxide, with the result
that affected infants and children suffer from severe recurrent
bacterial and fungal infections [3]. Catalase catalyzes toxic
hydrogen peroxide to water and oxygen (Fig. 2). Thus, non-
catalase producing bacteria such as Streptococcus pyogenes
are not likely to become major infectious agents in CGD
because they are killed by their own ROS in phagosomes.
However, catalase-producing bacteria such as Staphylo-
coccus aureus and Aspergillus fumigatus can cause life-
threatening infections in CGD patients [4].
Phagocyte NADPH oxidase is composed of a membrane-
spanning glycoprotein, cytochrome b558 and cytosolic pro-
teins, p47
phox, p67
phox, p40
phox, and a small G-protein, Rac [5].
Cytochrome b558, a heterodimeric protein composed of the
91-kDa glycoprotein (gp91
phox) and the 22-kDa protein
(p22
phox), is located in the plasma membrane of phagocytes
[6]. When the cells are stimulated, cytochrome b558 forms a
complex with cytosolic proteins and is activated to produce
superoxide (Fig. 1).
Superoxide produced by neutrophils can be detected
by cytochrome c reduction, NBT reduction, or calculated
from cyanide-insensitive O2 consumption [2, 7, 8]. In recent
years, the fluorescent probe dihydrorhodamine 123 (DHR)
has been widely used with the flow-cytometer to quantify
ROS produced by phagocytes [9, 10]. In case of chemilumi-
nescence (CL), Lucigenin-enhanced CL (LECL) is used
because it is one of the most sensitive and convenient
methods to detect reactive oxygen species (ROS) released
from various cells [11, 12]. We recently described the
mechanism by which Lucigenin detects ROS [13]. LECL,
however, is largely dependent upon the adhesion of neutro-
phils. Thus, a quantitative assay for ROS in cell suspensions
is needed.
In this study, we show that a mix of the CL probes
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Luminol and Diogenes detects ROS at a higher sensitivity
than Lucigenin. Both Luminol and Diogenes are usually
used alone to detect ROS, but we show that these probes
work together synergistically. Detection of ROS at a high
sensitivity will be useful in the clinic, where it is desirable
to use only small quantities of blood to diagnose neonatal or
pediatric diseases such as CGD.
MATERIALS AND METHODS
Materials
Diogenes was obtained from National Diagnostics
(Atlanta, USA). 5-amino-2,3-dihydro-1,4-phthalazinedione
(Luminol), bis-N-methylacridinium nitrate (Lucigenin),
superoxide dismutase (SOD), and phorbol myristate acetate
(PMA) were purchased from Sigma-Aldrich (St. Louis,
USA). Dextran was obtained from GE Health Care
(Piscataway, USA). Ficoll-Conray (specific gravity, 1.077)
was obtained from IBL (Fujioka, Japan).
Cell preparation
Peripheral blood was collected from healthy volunteers
who had given informed consent. Neutrophils were purified
from the peripheral blood as previously described [14].
Briefly, the cells were isolated by a combination of dextran
sedimentation, Ficoll-Conray gradient centrifugation, and
hypotonic treatment. Purified neutrophils were suspended
at 10
7 cells/ml in phosphate-buffered saline (PBS). Peri-
pheral B lymphocytes immortalized by Epstein-Barr virus
(EB-B cells) from a CGD patient and a healthy control were
kindly provided by Michio Nakamura (Nagasaki University).
The cells were maintained in RPMI1640 medium with 10%
fetal calf serum.
Fig. 1.  Schematic representation of phagocyte NADPH oxidase.
p47
phox, p67
phox and p40
phox bind each other and stay at cytosol in the “RESTING” state (left
side). Upon cell stimulation by phagocytosis for bacteria, the cytosolic proteins, including
small G-protein Rac, attach to membrane-bound cytochrome b558, and the oxidase becomes
“ACTIVATED” and produces superoxide anion.
Fig. 2.  Relations between several ROS and reaction enzymes.
(A) Molecular oxygen is reduced by phagocyte NADPH
oxidase to produce superoxide anion. (B) Superoxide is
reduced by dismutation to hydrogen peroxide and mole-
cular oxygen. (C) Hydrogen peroxide is subjected to
dismutation by catalase to become water and molecular
oxygen.43 T. Yamazaki et al.
CL assay
ROS signals were made chemiluminescent by one of
the following CL probes: Lucigenin (100 µM), Diogenes
(100× dilution from stock solution according to the manu-
facturer’s protocol), and/or Luminol (1 mM). For typical
measurements of CL, 5 × 10
4 neutrophils were incubated in
0.3 ml of assay buffer (PBS including 5 mM glucose, 1 mM
Mg
2+, 0.5 mM Ca
2+ and 0.05% BSA) for 3 min before addi-
tion of 200 ng/ml PMA. CL was monitored for 30 min using
the automatic luminescence analyzer VARIOSKAN FLASH
(Thermo Scientifc, Yokohama, Japan) or MiniLumat LB9506
(Berthold Japan, Tokyo) at 37°C. The assay was stopped
by the addition of SOD (0.1 mg (300U)/ml) to observe how
the CL was detected as superoxide. Other CL protocols are
described in the figure legends. For whole blood analysis,
several volumes of whole blood up to 1 µl were assayed in
0.3 ml of assay buffer.
RESULTS
Diogenes mixed with Luminol achieves higher sensitivity
detection of ROS than either reagent alone or Lucigenin
We have previously shown that ROS derived from
adhered neutrophils, but not neutrophils in suspension are
made chemiluminescent by Lucigenin [13]. Here, we com-
pared Lucigenin with the alternative CL probes Diogenes
and Luminol, alone or in combination. Neutrophils were
suspended in CL probe-containing assay buffers, seeded
into 96-well plates and incubated at 37°C for 3 min prior
to PMA stimulation. CL by Diogenes with Luminol was
approximately 50 times higher than that by Lucigenin (Fig. 3
and Table 1). The ratio of the PMA-stimulated CL of
Diogenes with Luminol to that of assays with Diogenes and
Luminol alone was approximately 4:1 and 5:1, respectively,
indicating that Diogenes and Luminol synergistically enhance
CL by ROS. PMA itself is an activator of protein kinase c
(PKC). Thus, to confirm that the CL is dependent on ROS,
we added SOD during the activation of neutrophils by
PMA. CL was greatly diminished after the addition of SOD
(Fig. 3), indicating that the PMA-dependent CL is due to
ROS from neutrophils.
Diogenes with Luminol is suitable for a quantitative assay
Precise quantitative measurement of ROS is necessary
for the diagnosis of CGD and may be prognostic for the
disease. Subsequently, therefore we next examined how the
CL assay with Diogenes and Luminol performs under con-
ditions of varying numbers of ROS-producing cells. ROS
released by 10 to 10
4 neutrophils was proportionally detected
according to cell numbers, which we propose could be
useful for CGD diagnosis (Fig. 4 and Table 2).
Diogenes with Luminol is a suitable reagent for the diag-
nosis of CGD
As CGD patients are typically neonates or young chil-
dren, it is desirable to perform diagnostic assays with small
quantities of blood. Therefore, we examined whether CL
measurement assays can be performed using whole blood.
Whole blood (0.4 µl) in 0.3 ml assay buffer showed signifi-
cant CL after PMA addition (Fig. 5A). B lymphocytes
produce superoxide at approximately 1% the rate produced
by neutrophils and are often immortalized by Epstein-Barr
(EB) virus for the purpose of future diagnosis. Therefore,
we examined whether ROS secretion by EB-B cells can be
detected using our CL assay. CL derived from control EB-B
cells could be detected, but CL was not detected in CGD
EB-B cells in response to PMA stimulation. These results
indicated that Diogenes with Luminol was a highly sensi-
tive reagent for ROS detection and suitable for CGD
Fig. 3.  Effect of Diogenes plus Luminol on CL.
Neutrophils (5 × 10
3 cells) were preincubated with
Lucigenin, Luminol, Diogenes, or Diogenes plus Luminol
at 37°C for 3 min before the addition of PMA. Superoxide
was eliminated by the addition of SOD (0.1 mg/ml) after
17 min incubation. The data are representative of results
from four independent experiments.
Table 1. Maximum CL by neutrophils after PMA stimulation
with four kinds of probe
Each value is the mean (± SD) obtained from four assays.
Experiments are described in Fig. 3.
Maximum cpm
Diogenes+Luminol: 77,536 (± 2,533)
Diogenes: 18,653 (± 761)
Luminol: 14,537 (± 1,210)
Lucigenin: 1,587 (± 127)44 Tropical Medicine and Health Vol.39 No.2, 2011
diagnosis. Furthermore, the result using CGD cells indicated
that the CL response was completely dependent on phago-
cyte NADPH oxidase alone and not on other enzymes
responding to PMA.
DISCUSSION
In this report, we show that CL assay using a combina-
tion of Diogenes and Luminol is highly sensitive to super-
oxide and that the CL observed is strongly ablated by the
addition of SOD. This method is approximately 50 times
more sensitive than the Lucigenin-based CL assay we
formerly analyzed [13]. It is still unknown how Diogenes
and Luminol act synergistically to elevate CL, but it is
unlikely that either reagent activates phagocyte NADPH
oxidase over PMA activation, which gives the oxidase
maximum activity. The two CL probes might excite each
other with superoxide. Although the mechanism behhind
the dramatic increase in CL using this assay remains unclear,
our present results demonstrate that higher CL levels are
emitted using Diogenes and Luminol in combination in
reaction to the same amount of energy source, here NADPH.
Fig. 4.  Effect of cell number on Diogene and Luminol depen-
dent CL.
Neutrophils (cell numbers indicated) were preincubated
with Diogenes plus Luminol at 37°C for 3 min before
the addition of PMA. CL at 7 (open circle) or 13 minutes
(closed square) after PMA stimulation is shown. The data
show the mean results of four independent experiments.
Table 2. Diogenes and Luminol dependent CL at 7 and 13 min after PMA stimulation
Each value is the mean (± SD) obtained from four assays. Experiments are described in Fig. 4.
10 100 1,000 10,000 (cells)
7 min: 273 (± 67) 2741 (± 437) 26888 (± 1939) 260732 (± 7426)
13 min: 308 (± 50) 3074 (± 519) 30519 (± 1722) 281797 (± 3114)
Fig. 5.  Effect of whole blood or EB-B cells on Diogene and Luminol dependent CL.
Peripheral whole blood samples (0.4 µl) were preincubated with Diogenes plus Luminol at 37°C for 3 min before the addition of
PMA, and CL was followed until 17 min. The data are representative of results from four independent experiments. (B) EB-B
cells (1 × 10
5 cells) from a control person (open circle) and a CGD patient (closed square) were preincubated with Diogenes
plus Luminol at 37°C for 3 min before the addition of PMA, and CL was followed until 18 min.45 T. Yamazaki et al.
Lucigenin, Luminol, and Diogenes react with ROS and
emit CL. The CL method is superior to other methods of
ROS detection such as NBT reduction, cytochrome c reduc-
tion and O2 consumption in that the CL probes are very
sensitive to ROS. However, it remains unclear which type
of ROS reacts with the CL probes. The validity of using the
CL method for assaying phagocyte NADPH oxidase is
demonstrated by the fact that CL by neutrophils from a
control person cannot be seen without additional stimula-
tion, such as via PMA or fMLP, and that CL cannot be
detected in assays of neutrophils from CGD patients with or
without stimulation.
In addition, we show that we can measure superoxide
from even a small amount of whole blood by this method,
which allows us to diagnose CGD in neonatal patients using
a single drop of whole blood. Another method using DHR
as a fluorescent probe is also highly quantitative and
convenient for the detection of ROS released by activated
neutrophils [9, 10]. The method also requires just a drop of
blood for diagnosis and can be applied to ROS by peripheral
monocytes but not by EB-B cells.
On another front, gene therapy for CGD has just begun
in clinical practice [15]. Immortalized B lymphocytes from
CGD patients are stable and useful for research in gene
therapy, but the weak activity of NADPH oxidase in B cells
has been inconvenient. Thus, a method to detect superoxide
produced by immortalized B lymphocytes from CGD
patients, as we describe here, may be a useful in vitro tool
for research in gene therapy as well as the diagnosis of CGD.
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